PRDM1 and neoplasm: To evaluate the effector functions of PRDM1 KO CAR T-cells in the setting of repetitive antigen exposure, we first assessed cytokine concentrations 24 hours after the first and fifth rounds of in vitro PC3-PSMA tumor cell stimulation.